Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.68 |
| ▸ | CTSS | P25774 | 4/20 | 0.68 |
| ▸ | CTSK | P43235 | 5/20 | 0.57 |
| ▸ | CTSB | P07858 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 2/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6389667 | 0.90 | CTSL (0.70) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL10663359 | 0.90 | CTSL (0.70) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL2678259 | 0.90 | CTSL (0.70) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL14561285 | 0.90 | CTSL (0.70) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL6389671 | 0.90 | CTSL (0.70) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL1491412 | 0.90 | CTSL (0.70) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL1491407 | 0.90 | CTSL (0.70) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL2678260 | 0.90 | CTSL (0.70) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL20538251 | 0.90 | CTSL (0.70) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL1285941 | 0.90 | CTSL (0.70) | CTSLCTSSCTSKCTSBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802946-B2 | NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2017-10-31 | — | — | US | disclosed |
| US-9593145-B2 | Secondary structure stabilized NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9512133-B2 | NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160115197-A1 | SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2016-04-28 | — | — | US | disclosed |
| US-20150336969-A1 | NMDA Receptor Modulators and Uses Thereof | NAUREX, INC. | 2015-11-26 | — | — | US | disclosed |
| US-9101612-B2 | Secondary structure stabilized NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150105364-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336969-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CTSL 4016/4885CTSS 4517/4885CTSK 3566/4885 |
| US-20150105364-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CTSL 4016/4885CTSS 4517/4885CTSK 3566/4885 |
| US-20160115197-A1 | SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2A, GRIN1, GRIN3A | CTSL 4593/4885CTSS 4529/4885CTSK 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.